Research programme: phosphodiesterase IVB inhibitors - Plexxikon

Drug Profile

Research programme: phosphodiesterase IVB inhibitors - Plexxikon

Alternative Names: PDE4B inhibitors research programme - Plexxikon; Phosphodiesterase IVB inhibitors research programme - Plexxikon; PLX 369; Research programme: PDE4B inhibitors - Plexxikon

Latest Information Update: 28 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plexxikon
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Inflammation

Most Recent Events

  • 04 Sep 2007 Lead development is ongoing
  • 16 Mar 2004 Plexxikon's PDE 4B inhibitor programme is available for partnering (
  • 16 Mar 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top